Supply Chain Intelligence

Monte Rosa Therapeutics, Inc. Supply Chain

GLUE supply chain intelligence for Monte Rosa Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

GLUE ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

9Suppliers
21Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

Monte Rosa Therapeutics, Inc. (GLUE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

33Total relationships
3Distinct source URLs
10High confidence
0.739Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Monte Rosa Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
NVS Novartis AG 90% Any costs for any co-funded development and commercialization activities are subject to budgets reviewed by the Company and Novartis.
NVS Novartis AG 90% Reciprocal relationship from NVS graph: Reciprocal relationship from GLUE graph: Any costs for any co-funded development and commercialization activities are subject to budgets reviewed by the Compan…
CCCC C4 Therapeutics, Inc. 72% current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t…
CCCC C4 Therapeutics, Inc. 72% Reciprocal relationship from CCCC graph: Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alter…
KYMR Kymera Therapeutics, Inc. 72% current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t…
KYMR Kymera Therapeutics, Inc. 72% Reciprocal relationship from KYMR graph: Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alter…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLUE graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLUE graph: delay, limit or prevent our devel…
NVSEF Novartis AG 72% delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects. In addition, some of our suppliers are located outside of the…
LAZRQ Luminar Technologies, Inc. 62% Reciprocal relationship from LAZRQ graph: ome (expense), net: Change in fair value of warrant liabilities — 1,069 (1,069 ) (100 )% Interest expense (48,190 ) (27,032 ) (21,158 ) 78 % Interest income …

Monte Rosa Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
NVS Novartis AG 92% Reciprocal relationship from NVS graph: Reciprocal relationship from GLUE graph: Reciprocal relationship from NVS graph: Reciprocal relationship from GLUE graph: Reciprocal relationship from NVS grap…
NVS Novartis AG 92% Pursuant to the 2025 Novartis Agreement, we granted to Novartis an exclusive, royalty-bearing, sublicensable and transferable license to degraders for one I&I program, or the First Licensed Program
ROCHE ROCHE 90% Pursuant to the License Agreement, the parties will seek to identify and develop MGDs against cancer or neurological disease targets using our proprietary drug discovery platform for an initial set o…
NVSEF Novartis AG 85% pany has identified certain performance obligations within the agreement as follows: • Performance obligations for the research and development of initial targets • Performance obligations for the re…
NVSEF Novartis AG 85% Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLUE graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLUE graph: Reciprocal relationship from NVSE…
CCCC C4 Therapeutics, Inc. 72% Reciprocal relationship from CCCC graph: Reciprocal relationship from GLUE graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from GLUE graph: current or future product candidate…
CCCC C4 Therapeutics, Inc. 72% current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t…
KYMR Kymera Therapeutics, Inc. 72% Reciprocal relationship from KYMR graph: Reciprocal relationship from GLUE graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from GLUE graph: Reciprocal relationship from KYMR g…
KYMR Kymera Therapeutics, Inc. 72% current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t…
NRIX Nurix Therapeutics, Inc. 72% current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t…
NRIX Nurix Therapeutics, Inc. 72% Reciprocal relationship from NRIX graph: Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alter…
AXA-LEBEN-AG AXA-LEBEN-AG 62% ncing. Liquidity considerations Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, and r…
C4-THERAPEUTICS-INC-NURIX-THERAPEUTICS-INC-KYMER C4-THERAPEUTICS-INC-NURIX-THERAPEUTICS-INC-KYMER 62% current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t…
COLUMNA-COLLECTIVE-FOUNDATION-GROUP COLUMNA-COLLECTIVE-FOUNDATION-GROUP 62% nt, the Company recognizes revenue from amounts allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses tha…
F-HOFFMAN-LA-ROCHE-LTD F-HOFFMAN-LA-ROCHE-LTD 62% ncing. Liquidity considerations Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, and r…
F-HOFFMANN-LA-ROCHE-LTD F-HOFFMANN-LA-ROCHE-LTD 62% meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those …
HOFFMAN-LA-ROCHE-INC HOFFMAN-LA-ROCHE-INC 62% ncing. Liquidity considerations Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff, and r…
HOFFMANN-LA-ROCHE-INC HOFFMANN-LA-ROCHE-INC 62% meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those …
MONTE-ROSA-THERAPEUTICS-AG MONTE-ROSA-THERAPEUTICS-AG 62% he U.S. would be entitled to the potential sales milestone payments and tiered royalties as sales outside of the U.S. Any costs for any co-funded development and commercialization activities are subj…
USA-LLC USA-LLC 62% ur disclosed and undisclosed programs including for CDK2 and CCNE1. We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development…
WINCASA-AG WINCASA-AG 62% it rate, management estimated the incremental borrowing rate based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. The …

Monte Rosa Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
GLUE-DEBT Debt stack $39.1M 90% Market cache reports total debt of $39.1M.
GLUE-DEBT-9808 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-06-30.

Monte Rosa Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Monte Rosa Therapeutics, Inc..

Monte Rosa Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
GLUE-OWNER-NEA-MANAGEMENT-COMPANY-LLC NEA Management Company, LLC 90% 13F overlay lists NEA Management Company, LLC as top holder; 191 tracked holders.

Monte Rosa Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
HLNCF Haleon plc 100.00 2
JBIO Jade Biosciences, Inc. 100.00 2
ABT Abbott Laboratories 100.00 2
COLL Collegium Pharmaceutical, Inc. 100.00 2
GILD Gilead Sciences, Inc. 100.00 2
HLN Haleon plc 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
ELVN Enliven Therapeutics, Inc. 100.00 2
CRIS Curis, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
SLGL Sol-Gel Technologies Ltd. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
KLRS Kalaris Therapeutics, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Monte Rosa Therapeutics, Inc..

Unlock full GLUE data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
GLUE
Unlock GLUE Supply Chain Data
Verified relationships include:
NVSNovartis AGSupplier90%
NVSNovartis AGSupplier90%
NVSNovartis AGCustomer92%
NVSNovartis AGCustomer92%
+29 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →